To find out more please visit our website:

www.archiestudy.com

or contact a member of the ARCHIE study team:

Tricia Carver—Trial Manager

Dr Kay Wang—Principal Investigator

Nuffield Department of Primary Health Care Sciences
University of Oxford
23-38 Hythe Bridge Street
Oxford, OX1 2ET

Email: archie@phc.ox.ac.uk
Tel: 01865 617 842

The early use of Antibiotics in ‘at Risk’ CHildren with InfluEnza

Archie is more ill than usual when he just gets a cold or flu........

......... but I’m not sure he is ill enough to need antibiotics

Sounds familiar?

www.archiestudy.com

This study is funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme
(Grant Reference RP-PG-1210-12012)
Why are we doing the ARCHIE study?

We would like to find out whether giving an antibiotic called co-amoxiclav to ‘at risk’ children aged 6 months to 12 years early on when they have flu or flu-like illness might:

1. Help stop them from developing bacterial infections and becoming more unwell.
2. Help them get better more quickly.
3. Affect how well antibiotics work against similar infections in future.

‘At risk’ children with a long-term medical condition or disability are particularly prone to developing bacterial infections if they get flu or a flu-like illness.

What will happen if my child and I decide to take part?

Your doctor or nurse will:

- Ask you some questions about your child’s flu-like illness
- Test to see whether your child has the flu virus by taking a swab from his/her nose
- Test to see whether your child has any bacterial infections by taking a swab from his/her throat
- Give your child a 5-day course of medication (either co-amoxiclav or a ‘placebo’ which looks & tastes the same but does not contain the antibiotic)
- Give you a study diary to fill in

What is co-amoxiclav?

Co-amoxiclav is a type of penicillin antibiotic. It has a wider effect than ordinary penicillin and is used to treat many types of bacterial infections in children like chest, ear, throat and sinus infections.

At the moment, co-amoxiclav is not licensed to treat children early on in a flu-like illness to try and prevent them from coming down with bacterial infections.

The ARCHIE study will help us to find out whether co-amoxiclav can help ‘at risk’ children in this way.

www.archiestudy.com